• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?

作者信息

Di Noia Vincenzo, D'Aveni Alessandro, Squadroni Michela, Beretta Giordano Domenico, Ceresoli Giovanni Luca

机构信息

Department of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy.

Department of Medical Oncology, Cliniche Humanitas Gavazzeni, 24125 Bergamo, Italy.

出版信息

Lung Cancer. 2020 Jul;145:208-210. doi: 10.1016/j.lungcan.2020.05.006. Epub 2020 May 11.

DOI:10.1016/j.lungcan.2020.05.006
PMID:32439211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7211674/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d99/7211674/ed4dd4782f9a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d99/7211674/ed4dd4782f9a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d99/7211674/ed4dd4782f9a/gr1_lrg.jpg

相似文献

1
Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?SARS-CoV-2感染的癌症患者中的免疫检查点抑制剂：点燃战火的火花？
Lung Cancer. 2020 Jul;145:208-210. doi: 10.1016/j.lungcan.2020.05.006. Epub 2020 May 11.
2
Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.在新冠疫情期间，类似新冠病毒感染的检查点抑制剂肺炎。
Lung Cancer. 2020 Aug;146:376-377. doi: 10.1016/j.lungcan.2020.06.013. Epub 2020 Jun 17.
3
Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.在 COVID-19 大流行期间的节拍口服长春瑞滨和肺癌治疗：单中心经验。
Lung Cancer. 2020 Jul;145:83-84. doi: 10.1016/j.lungcan.2020.05.001. Epub 2020 May 6.
4
A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?一名患有严重中性粒细胞减少症的晚期肺癌患者新冠肺炎的良好预后：免疫抑制是SARS-CoV-2感染的危险因素吗？
Lung Cancer. 2020 Jul;145:213-215. doi: 10.1016/j.lungcan.2020.04.029. Epub 2020 May 4.
5
Blood vessel injury may spur disease's fatal second phase.血管损伤可能会引发疾病致命的第二阶段。
Science. 2020 Jun 5;368(6495):1039-1040. doi: 10.1126/science.368.6495.1039.
6
Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.一名感染严重急性呼吸综合征冠状病毒2的肺癌患者的治疗及预后
J Thorac Oncol. 2020 May;15(5):e63-e64. doi: 10.1016/j.jtho.2020.02.025. Epub 2020 Mar 6.
7
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.接受纳武单抗治疗的老年黑色素瘤患者的新型冠状病毒肺炎感染临床病程
J Oncol Pharm Pract. 2020 Jul;26(5):1289-1294. doi: 10.1177/1078155220924084. Epub 2020 May 19.
8
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
9
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
10
COVID-19: the use of immunotherapy in metastatic lung cancer.新型冠状病毒肺炎：免疫疗法在转移性肺癌中的应用
Immunotherapy. 2020 Jun;12(8):545-548. doi: 10.2217/imt-2020-0096. Epub 2020 Apr 30.

引用本文的文献

1
SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.癌症患者接受免疫检查点抑制剂治疗时的 SARS-CoV-2 感染和 COVID-19 疫苗接种。
Cell Death Dis. 2023 Jun 30;14(6):390. doi: 10.1038/s41419-023-05922-w.
2
Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.SARS-CoV-2 通过上调 PD-L1 促进免疫逃逸。
J Med Virol. 2023 Feb;95(2):e28478. doi: 10.1002/jmv.28478.
3
Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era.COVID-19 大流行期间肿瘤学中免疫检查点抑制剂管理的利弊

本文引用的文献

1
ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19.吸烟者和 COPD 患者小气道上皮中的 ACE-2 表达：对 COVID-19 的影响。
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.00688-2020. Print 2020 May.
2
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: .在 SARS-CoV-2 大流行期间我们如何治疗肺癌患者：。
ESMO Open. 2020 Apr;5(2):e000765. doi: 10.1136/esmoopen-2020-000765.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Cancers (Basel). 2021 Apr 15;13(8):1906. doi: 10.3390/cancers13081906.
4
Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis.抗肿瘤治疗对 SARS-CoV-2 感染癌症患者的影响：系统评价和荟萃分析。
Cancer Med. 2021 Mar;10(5):1644-1655. doi: 10.1002/cam4.3754. Epub 2021 Feb 6.
5
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?肺癌的感染与免疫治疗：一段糟糕的关系？
Int J Mol Sci. 2020 Dec 22;22(1):42. doi: 10.3390/ijms22010042.
6
Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.面对 COVID-19 时癌症患者免疫检查点治疗的管理。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001593.
7
Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection.SARS-CoV-2感染时代的癌症与免疫检查点抑制剂治疗
Cancers (Basel). 2020 Nov 16;12(11):3383. doi: 10.3390/cancers12113383.
8
A Nasopharyngeal Carcinoma Patient With COVID-19 Infection After Immunotherapy: A Case Report and Literature Review.免疫治疗后感染 COVID-19 的鼻咽癌患者：病例报告及文献复习。
In Vivo. 2020 Nov-Dec;34(6):3753-3756. doi: 10.21873/invivo.12225.
9
The Landscape of COVID-19 in Cancer Patients: Prevalence, Impacts, and Recommendations.癌症患者中的新冠疫情状况：患病率、影响及建议
Cancer Manag Res. 2020 Sep 23;12:8923-8933. doi: 10.2147/CMAR.S272008. eCollection 2020.
10
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?2019冠状病毒病大流行期间的癌症管理：基于免疫检查点抑制剂的免疫疗法有害还是有益？
Cancers (Basel). 2020 Aug 10;12(8):2237. doi: 10.3390/cancers12082237.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
COVID-19 and Italy: what next?COVID-19 和意大利：下一步如何？
Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.
5
Coronaviruses: Facts, Myths, and Hypotheses.冠状病毒：事实、误解与假说
J Thorac Oncol. 2020 May;15(5):675-678. doi: 10.1016/j.jtho.2020.02.024. Epub 2020 Mar 7.
6
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
7
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
8
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
9
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.临床证据不支持使用皮质类固醇治疗2019新型冠状病毒肺炎肺损伤。
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
10
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.胸部恶性肿瘤中免疫检查点抑制剂相关的免疫不良反应：聚焦于非小细胞肺癌患者。
J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52.